(S)-6-[(4-Chlorophenyl)(1H-1,2,4-triazol-1-yl)methyl]-1-[11C]methyl-1H-benzotriazole
OA: gold
AI-generated summary
Lidstrom et al. synthesized the PET radioligand [11C]vorozole from nor-vorozole to investigate aromatase activity in tissues including endometrium, which is overexpressed in endometriosis.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Aromatase is an enzyme complex of the cytochrome P450 superfamily (1). It is composed of P450 and a flavoprotein called NADPH-P450 reductase. Its main function is to aromatize androgens to estrogens. Aromatase is present in many tissues, including granulosa cells of the ovary, brain, fat, placenta, blood vessels, skin, bone, and endometrium. Aromatase is overexpressed in tissue of endometriosis, uterine fibroids, breast cancer, and endometrial cancer (2-6). (S)-6-[(4-Chlorophenyl)(1H-1,2,4-triazol-1-yl)methyl]-1-methyl-1H-benzotriazole (vorozole) is an aromatase inhibitor with a inhibition constant (Ki) value of 1 nM. Lidstrom et al. (7) prepared [11C]vorozole by N-methylation of (S)-6-[(4-chlorophenyl)(1H-1,2,4-triazol-1-yl)methyl]-1H-benzotriazole (nor-vorozole) to use as a positron emission tomography (PET) radioligand to study aromatase activity.
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- europepmc
- last seen: 2026-11-06T06:14:58.568748+00:00